异丙酚预处理对全脑缺血再灌注大鼠脑组织S100β和神经元特异性烯醇化酶的影响  

Effects of propofol pretreatment on S100β and neurosecretion enzyme in rat brain tissues with global cerebral ischemia-reperfusion

作　　者：甘国胜[1] 段玮[1] 姜立[2] 陈利民[1] 吴明春[1] 陈敏[1] 

机构地区：[1]广州军区武汉总医院麻醉科,武汉430070 [2]武汉大学生化教研室

出　　处：《解放军医学杂志》2006年第11期1066-1067,共2页Medical Journal of Chinese People's Liberation Army

摘　　要：目的探讨异丙酚预处理对全脑缺血再灌注大鼠脑组织S100β及神经元特异性烯醇化酶(NSE)含量的影响,评价异丙酚对脑组织的保护作用。方法30只雄性SD大鼠,随机分为假手术组(A组)、单纯脑缺血再灌注组(B组)和缺血前2h异丙酚预处理组(C组),每组10只,C组动物在缺血前腹腔注射异丙酚100mg/kg,采用线栓法制作全脑缺血再灌注模型,于脑缺血再灌注后24h评估并记录动物的神经行为学评分,测定大鼠脑组织S100β和NSE含量。结果异丙酚预处理组神经行为学评分较单纯脑缺血再灌注组高(P<0·05),假手术组评分也明显高于单纯脑缺血再灌注组(P<0·05),异丙酚预处理组脑组织中S100β和NSE含量明显低于单纯脑缺血再灌注组(P<0·05)。结论异丙酚可以降低脑缺血再灌注损伤大鼠脑组织S100β和NSE的含量,减轻神经损害,缺血前2h异丙酚预处理可以改善大鼠脑缺血再灌注损伤后的神经行为学评分,有明显的脑保护作用。Objective To study the effects of propofol pretreatment on S100β and enzyme （NSE） of brain tissues with global cerebral ischemia-reperfusion in rat, and to evaluate the effects of propofol in protection of brain. Methods 30 SD male rats were randomly divided into 3 groups： sham operation group （group A, n = 10）; single cerebral ischemia-reperfusion group （group B, n = 10）; propofol pretreatment at 2h before ischemia group （group C, n = 10）, in which propofol （100mg/kg） was given intraperitoneally （ip） before ischemia. 24h after ischernia-reperfusion, the neuroethology scores were recorded and evaluated, and S100β and NSE in rat brain were determined. Results The nettroetbology scores of group A were higher than those of group B （P〈0.05）, and the scores of group C were also significantly higher than those of group B （P〈0.05）. The S100β and NSE in the rats of group C were significantly lower compared to those of group B （P〈0.05）. Conclusion Propofol could reduce S100β and NSE in rat＇s brain with global cerebral ischemia-reperfusion, and alleviate neural lesions. The neuroethology scores may be improved, and a promising brain-protective effect may be achieved with propofol pretreatment at 2h before ischemia.

关 键 词：异丙酚 再灌注损伤 S100蛋白质类 磷酸丙酮酸水合酶 

分 类 号：R971.2[医药卫生—药品] R651.15[医药卫生—药学]